Respiratory Syncytial Virus in babies

Hvivo, a pharmaceutical services company formerly known as Open Orphan, said it remained on track to hit its future growth targets after another record year in 2023. The company is set to begin paying annual dividends,

Healthcare company hVIVO, formerly Open Orphan, has reported higher revenues and earnings for 2023 and said it had a robust orderbook for this year. The company – which tests infectious and respiratory disease products using human

hVIVO plc, a specialist in testing infectious and respiratory disease products using human challenge clinical trials, has reported a 16% increase in revenue for 2023 to £56m. The company, listed on AIM in London and Euronext

Pharmaceutical services firm Hvivo, formerly Open Orphan, reported a 44pc rise in earnings in 2023 in a “record year across all financial and operational metrics.” Earnings before interest, taxes, depreciation and amortisation (Ebitda) increased to £13m

Introduction A biotech company developing a treatment for cancer and immune disorders planned to conduct their Phase 1b clinical trial in the United States (US). They approached Venn Life Sciences seeking a partner to provide comprehensive

Andrew will be discussing new advances in respiratory virus challenge models improving their value for vaccine efficacy testing and host response disease monitoring. The World Vaccine Congress is an award-winning series of conferences and exhibitions that

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

Clinical trials are essential processes in the field of medicine, helping to determine the safety and effectiveness of new treatments, drugs, or medical procedures. These trials involve volunteers who agree to participate in the study under carefully controlled

Despite scientific progress made in the last decades, nearly 1 billion of individuals are affected by tropical diseases yearly, according to the World Health Organization. The development of new vaccines for tropical diseases remains difficult and

Canary Wharf is set to receive a multi-million-pound cash injection to build more homes in the capital’s banking district. As part of the Spring Budget, Chancellor Jeremy Hunt announced he would pour over £242m into developing homes in

It’s no secret that women across a spectrum of industries often face challenges when trying to get ahead and make their mark in the business marketplace. The business development field in particular is typically heavily dominated

hVIVO plc (LON:HVO), a name not often headlined among the largest market cap companies, has recently led the AIM gainers, catching the eye of shareholders and investors alike. This surge in share price, despite not reaching

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater

A leading firm testing infectious diseases, hVIVO, has reported a record year as it looks to start work on an £80m orderbook in 2024. The London-listed firm said it achieved revenue of £56m for the full

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

Healthcare company hVIVO, formerly Open Orphan, said today it expects to report full year revenues of £56m for 2023, a 15.5% increase on the £48.5m reported in 2022. The company said the figure is slightly ahead